ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
A combination of Nrf-2 activator, kinetin and zinc provides neuroprotection through NLRP3-NF-ԟB signaling in traumatic brain injury.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nuclear erythroid 2-related factor (Nrf-2) activators have been used in previous research in inhibiting the multifaceted pathophysiology of traumatic brain injury (TBI). Moreover, combinatorial treatment strategies provide an additive pharmacological effect when compared with single treatment against brain injury. Therefore, the current study aimed to evaluate the neuroprotective effect of a Nrf-2 activator, kinetin (plant cytokinin, 6-Furfurylaminopurine) and zinc along with their combination on pre-clinical TBI. The acute injury was induced in male Wistar rats by controlled cortical impact and kinetin (5 mg/kg and 10 mg/kg) along with zinc picolinate (6 mg/kg) was administered. Several neurobehavioral tests like open field, beam balance and grip strength were performed post injury. Biochemical, histopathological and immunohistochemical analysis were also carried out. The expression of NLRP3-NF-ԟB pathway proteins were evaluated using techniques like ELISA and immunohistochemistry. Histopathological analysis was performed through H & E staining method. The results showed less exploration and grip strength in injured rats which was improved after treatment with kinetin. Injured rats showed a slight increase in brain and serum Nrf-2 levels which was profoundly increased by treatment. We also found an increase in brain and serum levels of an antioxidant defence system and a decrease in levels of inflammatory cytokines after treatment with both kinetin and zinc picolinate. There was a significant decrease in levels of NF-ԟB and NLRP3 inflammasome. Further, histopathological and immunohistochemistry analysis revealed neuroprotective effect of both the compounds on TBI. We can conclude that kinetin and zinc, alone and their combination show neuroprotective effects in TBI by activating Nrf-2 anti-oxidant defence and inhibiting NLRP3-NF-ԟB pathways. These findings support future evaluation of plant cytokinin in combination with a bio metal in attenuating secondary injury in TBI.
Indexed as
Identifiers
42446569What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.